Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.52 |
| ▸ | CA12 | O43570 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.45 |
| ▸ | CA4 | P22748 | 4/20 | 0.45 |
| ▸ | CA6 | P23280 | 4/20 | 0.45 |
| ▸ | CA5A | P35218 | 4/20 | 0.45 |
| ▸ | CA7 | P43166 | 4/20 | 0.45 |
| ▸ | CA9 | Q16790 | 4/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8747645 | 0.83 | CTDSP1 (0.49) | CA2TRPA1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL18741085 | 0.82 | CA2 (0.53) | CA2CA12CA1CA4CA6 | |
| SCHEMBL7904621 | 0.81 | CA2 (0.52) | CA2CA12CA1CA4CA7 | |
| SCHEMBL29469901 | 0.81 | CA2 (0.52) | CA2CA12CA1CA4CA7 | |
| SCHEMBL1805970 | 0.79 | CA2 (0.50) | CA2CA12CA1CA7CA9 | |
| SCHEMBL289875 | 0.79 | CA2 (0.50) | CA2CA12CA1CA4CA6 | |
| SCHEMBL1805969 | 0.79 | CA2 (0.50) | CA2CA12CA1CA4CA6 | |
| SCHEMBL9174184 | 0.78 | CA2 (0.53) | CA2CA12CA1CA4CA6 | |
| SCHEMBL4953473 | 0.78 | CA1 (0.54) | CA2CA12CA1CA4CA6 | |
| SCHEMBL22015596 | 0.77 | PDIA6 (0.53) | CA2CA12CA1CA6CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| CN-1659161-A | Piperidine derivatives having CCR3 antagonism | TEIJIN LTD (JP) | 2005-08-24 | — | — | CN | disclosed |
| EP-1502916-A1 | PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | CA2 1068/4885CA12 3636/4885CA1 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.